
PGY-3 General Surgery @UCIrvineSurgery | Researcher @MGHSurgery @CedarsSinai Ferrone Lab | Interested in CGSO, HPB Surgery, Cancer Immunology & Immunotherapy
Los Angeles, CA
Joined January 2021
- Tweets179
- Following517
- Followers268
- Likes1.1K
Marco Ventin MD retweeted
In a single-institution study after distal pancreatectomy, fluid collections developed in 53% of patients, but only approximately one fourth were associated with clinically relevant postoperative pancreatic fistula. ovid.com/10.1097/SLA.0000000…
Nature research paper: Hepatocytes promote liver metastasis of pancreatic cancer by providing serine
go.nature.com/4hwk1v4
Marco Ventin MD retweeted
#AudioVisualAbstract : Augmenting the Future Liver Remnant Prior to Major #Hepatectomy : A Review of Options on the Menu @laleh_melstrom
rdcu.be/feIGV
@jhatjhmi1
@SyedAAhmad5
Love our group!!!
Scrubs off, harnesses on! Our surgical residents took a break from the OR for some wellness, teamwork, and a little adventure at the ropes course! Because sometimes the best way strengthen the team is to get out of the OR and hang out — literally! #teambuilding #residentwellness
Marco Ventin MD retweeted
How to manage chronic corticosteroid therapy before pancreatic surgery?
🔥 Increased morbidity burden and 5× higher mortality
🗣️ Preoperative counselling is essential
🤝 Multidisciplinary, risk-adapted perioperative planning
sciencedirect.com/science/ar…
Very valuable resource for medical students and residents approaching HPB rotations
The SSO Medical Student & Trainee Primer for Hepatopancreatobiliary Surgical Oncology is now published in @SurgOncInsight! This is the second of three primers released by members of the 2025–2026 Fellows and Young Attending Committee.
Read now: ow.ly/zSrz50XY9Xf
Does surgery have a role in metastatic WD G3 GEP-NETs?
Our new @AnnSurgOncol study of 3,198 patients suggests yes, but pt selection is key. G3 alone should not preclude surgical consideration in carefully selected patients. @ThomasSuttonMD @AGangiMD
link.springer.com/article/10…
Marco Ventin MD retweeted
FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by @DanaFarber and Brian Wolpin, MD, MPH, of @DanaFarber_Hale
Marco Ventin MD retweeted
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study - thelancet.com/journals/lanon…
Marco Ventin MD retweeted
Society of Surgical Oncology
Careers in Surgical Oncology
Thursday, September 10 at 6:00 PM CST
Speaker and Bio Link: surgonc.org/education/upcomi…
Registration Link: us06web.zoom.us/meeting/regi…
Marco Ventin MD retweeted
Congratulations Paolo! So well deserved! Grazie for all of your contributions to SITC and the field. @UNC_Lineberger
It's an honor to present Paolo Antonio Ascierto, MD of Università degli Studi di Napoli Federico II, Naples, Italy with the 2026 SITC Lifetime Achievement Award. Thank you for your support of SITC and significant contributions to advancing the #IO field. sitcancer.org/awards
Marco Ventin MD retweeted
We have long known that patients with cystic pancreatic NETs fare better after resection and have lower risk of recurrence. Also, cystic pNETs are less likely to have high-risk features such as nodal metastases. What has been missing is a really large study... We have that now.
Multi-institutional study of 1727 patients, including 177 cystic pNETs with comparison across groups.
If you take care of patients with pNETs, this is a must read!
Key findings include:
-- Cystic PanNETs demonstrated significantly fewer high risk histopathologic features
-- Lymph node (LN) metastases (5.5% vs 24.0%, P < 0.001)
-- Distant recurrence (4.1% vs 14.4%; P <0.001)
-- Among tumors, ≤3 cm, cystic PanNETs had a low rate of LN metastases (3.9% vs 17.8%; P < 0.001)
-- Recurrence (3.1% vs 8.4%; P = 0.041), and low propensity to recur distantly
-- Cystic PanNETs had favorable long-term survival regardless of tumor size.
oce.ovid.com/article/0000065…
@MVentinMD @jhatjhmi1
Marco Ventin MD retweeted
DUPAN-2 was an effective surrogate biomarker for monitoring treatment response in patients with #PancreaticCancer who are carbohydrate antigen 19-9 nonexpressors, and normal levels were associated with improved outcomes.
ja.ma/4xissRB
Exciting to see our manuscript out @JournalofExper1 B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response in preclinical models. @MGHSurgery @CedarsSinaiMed @curecc link.springer.com/article/10…
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Marco Ventin MD retweeted
Drain fluid amylase levels on postoperative days 1 and 3 accurately estimated the risk of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. journals.lww.com/annalsofsur…
Marco Ventin MD retweeted
When do you operate on a PanNET?
A tough and nuanced call 😳
🦓 Unpacking that with @EAHPBA x @SocSurgOnc x @NANETS1 with @spartelli @decsamethasone @valentinandreas
📝 We will be drawing from recent @BJSurgery NETs commission paper
⏰May 21, 18:00 CEST - 🆓 registration 👇🏻
🚨 E-AHPBA Grand Rounds next week
Uncertainty and Decisions in the Surgical Management of PanNETs
📅 21 May 2026
🕕 18:00 CEST
💻 Free to attend
Don’t miss this engaging session in collaboration with SSO and NANETS - programme and registration details below 👇
🔗 eahpba.org/education-and-tra…
#EAHPBAGrandRounds #PanNETs #HPBSurgery #SurgicalOncology
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma | @NEJMClinician nejm.org/doi/full/10.1056/NE…
A very high yield read - Surgical management of pancreatic neuroendocrine tumours | BJS | Oxford Academic @BJSurgery @HalletJulie academic.oup.com/bjs/article…



































